Inactivated and subunit vaccines against porcine reproductive and respiratory syndrome: Current status and future direction
- PMID: 25980425
- DOI: 10.1016/j.vaccine.2015.04.102
Inactivated and subunit vaccines against porcine reproductive and respiratory syndrome: Current status and future direction
Abstract
Within a few years of its emergence in the late 1980s, the PRRS virus had spread globally to become the foremost infectious disease concern for the pork industry. Since 1994, modified live-attenuated vaccines against porcine reproductive and respiratory syndrome virus (PRRSV-MLV) have been widely used, but have failed to provide complete protection against emerging and heterologous field strains of the virus. Moreover, like many other MLVs, PRRSV-MLVs have safety concerns including vertical and horizontal transmission of the vaccine virus and several documented incidences of reversion to virulence. Thus, the development of efficacious inactivated vaccines is warranted for the control and eradication of PRRS. Since the early 1990s, researchers have been attempting to develop inactivated PRRSV vaccines, but most of the candidates have failed to elicit protective immunity even against homologous virus challenge. Recent research findings relating to both inactivated and subunit candidate PRRSV vaccines have shown promise, but they need to be pursued further to improve their heterologous efficacy and cost-effectiveness before considering commercialization. In this comprehensive review, we provide information on attempts to develop PRRSV inactivated and subunit vaccines. These includes various virus inactivation strategies, adjuvants, nanoparticle-based vaccine delivery systems, DNA vaccines, and recombinant subunit vaccines produced using baculovirus, plant, and replication-deficient viruses as vector vaccines. Finally, future directions for the development of innovative non-infectious PRRSV vaccines are suggested. Undoubtedly there remains a need for novel PRRSV vaccine strategies targeted to deliver cross-protective, non-infectious vaccines for the control and eradication of PRRS.
Keywords: Cross-protection; Delivery system; Immunity; Inactivated/killed PRRSV; Porcine reproductive and respiratory syndrome virus (PRRSV).
Copyright © 2015 Elsevier Ltd. All rights reserved.
Similar articles
-
Live porcine reproductive and respiratory syndrome virus vaccines: Current status and future direction.Vaccine. 2015 Aug 7;33(33):4069-80. doi: 10.1016/j.vaccine.2015.06.092. Epub 2015 Jul 4. Vaccine. 2015. PMID: 26148878 Review.
-
Novel strategies and approaches to develop the next generation of vaccines against porcine reproductive and respiratory syndrome virus (PRRSV).Virus Res. 2010 Dec;154(1-2):141-9. doi: 10.1016/j.virusres.2010.07.020. Epub 2010 Jul 23. Virus Res. 2010. PMID: 20655962 Free PMC article. Review.
-
Recombinant Porcine Reproductive and Respiratory Syndrome Virus Expressing Membrane-Bound Interleukin-15 as an Immunomodulatory Adjuvant Enhances NK and γδ T Cell Responses and Confers Heterologous Protection.J Virol. 2018 Jun 13;92(13):e00007-18. doi: 10.1128/JVI.00007-18. Print 2018 Jul 1. J Virol. 2018. PMID: 29643245 Free PMC article.
-
Plasmid containing CpG oligodeoxynucleotides can augment the immune responses of pigs immunized with porcine reproductive and respiratory syndrome killed virus vaccine.Vet Immunol Immunopathol. 2010 Aug 15;136(3-4):257-64. doi: 10.1016/j.vetimm.2010.03.015. Epub 2010 Mar 25. Vet Immunol Immunopathol. 2010. PMID: 20394988
-
Porcine reproductive and respiratory syndrome (PRRS) virus-specific interferon-gamma(+) T-cell responses after PRRS virus infection or vaccination with an inactivated PRRS vaccine.Viral Immunol. 2005;18(2):381-9. doi: 10.1089/vim.2005.18.381. Viral Immunol. 2005. PMID: 16035950
Cited by
-
Immunological evaluation of recombination PRRSV GP3 and GP5 DNA vaccines in vivo.Front Cell Infect Microbiol. 2022 Oct 6;12:1016897. doi: 10.3389/fcimb.2022.1016897. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 36275018 Free PMC article.
-
Antiviral activity of recombinant porcine surfactant protein A against porcine reproductive and respiratory syndrome virus in vitro.Arch Virol. 2016 Jul;161(7):1883-90. doi: 10.1007/s00705-016-2838-3. Epub 2016 Apr 21. Arch Virol. 2016. PMID: 27101074 Free PMC article.
-
Efficacy of the Synergy Between Live-Attenuated and Inactivated PRRSV Vaccines Against a NADC30-Like Strain of Porcine Reproductive and Respiratory Syndrome Virus in 4-Week Piglets.Front Vet Sci. 2022 Feb 2;9:812040. doi: 10.3389/fvets.2022.812040. eCollection 2022. Front Vet Sci. 2022. PMID: 35187144 Free PMC article.
-
Respiratory nanoparticle-based vaccines and challenges associated with animal models and translation.J Control Release. 2015 Dec 10;219:622-631. doi: 10.1016/j.jconrel.2015.09.047. Epub 2015 Sep 26. J Control Release. 2015. PMID: 26410807 Free PMC article. Review.
-
Prediction and in vitro verification of potential CTL epitopes conserved among PRRSV-2 strains.Immunogenetics. 2017 Oct;69(10):689-702. doi: 10.1007/s00251-017-1004-8. Epub 2017 Jun 7. Immunogenetics. 2017. PMID: 28589207 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources